cancel
Showing results for 
Search instead for 
Did you mean: 

Harnessing the immune system to control prostate cancer spread to bone

PCFA Staff
0 2 128

28 April 2020  

By Dr Jacqueline Schmitt - Manager, Research Programs for PCFA

In a ground-breaking discovery for men with aggressive prostate cancer, Australian scientists have found a new way to make prostate cancer cells that have spread to bone more visible, so that the immune system can more easily recognise and kill them.

The scientists found that the use of an existing drug could reprogram cancer cells to produce proteins that make the cells identifiable for targeting by immune cells. Impressively, the therapy not only blocked the growth of cancers in the bone, it also established immune memory, serving as greater protection against cancer recurrence. While further research is still needed, this approach may one day be used to make immunotherapy more effective for the treatment of aggressive prostate cancers.

Growth of prostate cancers cells in bone, known as bone metastases, occurs in up to 90% of men whose prostate cancer has become resistant to treatment. Bone metastases can occur many years after a man is first diagnosed and treated and scientists believe that these tumour growths are due to dormant prostate cancer cells or sleeping cancer cells. We have written about dormant cancer cells previously in an article called “Why cancer cells go to sleep”.4543286370?profile=RESIZE_400x

It is very difficult to detect dormant cancer cells. These tumours are often small and don’t produce symptoms, so patients are often unaware of them and conventional diagnostic tools are unable to “see” them. Dormant cancer cells also commonly operate in slow-metabolism mode, so even sophisticated diagnostic techniques, such as PET scans, may not pick up these tumours.

Interestingly, the real challenge lies not just in detecting these dormant cancer cells, but in stopping them from “waking up” and growing into large destructive tumours.

The project was led by scientists at the Peter MacCallum Cancer Centre, in collaboration with LaTrobe University, Garvan Institute of Medical Research and the University of Melbourne. Click here to read more about the project.

The scientists used a mouse model of prostate cancer to study dormant cancer cells in bone. In this model prostate cancer cells called RM1 cells were injected into the mice. These cells move through the blood and settle on the bones where over time they form bone metastases. Animal models like this are very important for scientists to study diseases like cancer. Before being injected into the mice, the RM1 cells were modified with a special dye system that allowed the scientists to “see” the cancer cells in bone using PET scans and differentiate dormant cancer cells from those that were growing.

The scientists were able to locate areas of bone harbouring prostate cancer cells and remove the cells to study the differences between dormant and growing cells. To do this they used a sophisticated state-of-the-art single cell sequencing technique that allowed the characteristics of individual cells to be examined. They found important differences between the cells.

Prostate cancer cells that had remained dormant in the mouse bones were found to express genes that made the cells susceptible to being attacked by the mouse’s immune system, but in the growing cancer cells, these genes had been switched off. Many of these genes make proteins that are part of the important type I interferon (IFN) pathway. If IFN is inactive, the immune system does not see the cell as a threat so it will ignore it allowing the tumour to continue to grow.

The scientists went on to study prostate cancer bone metastasis samples removed from men being treated for castrate resistant prostate cancer. These men generously agreed to donate samples of their cancer for medical research. The scientists compared the primary tumours removed from the prostate with the bone metastasis tumours and found that genes associated with immune response including those associated with IFN signalling were reduced in the metastasis samples compared to the primary tumour.

‘The confirmation that IFN was important for outgrowth of bone metastases in men with prostate cancer prompted us to look for ways to reactivate IFN production in the actively dividing cancers,’ says Dr Katie Owen from Peter Mac, who led the study.

From their observations in the mouse and human studies, the scientists hypothesised that restoring IFN function would stop the cancer cells that were growing in bone. They decided to test drugs from a family of drugs called HDAC inhibitors. HDAC inhibitors have many effects on cancer cells and make them more susceptible to being attacked and killed by the immune system.

Through a series experiments, the research team found that the HDAC inhibitor Entinostat effectively restored IFN function and prevented the growth of prostate cancer cells in bone by increasing immune signals in the cells. In the mice studies, Entinostat was found to reactivate IFN in prostate cancer bone metastases slowing their growth and increasing the survival time of the mice when compared to mice not treated with the drug.

Importantly, Entinostat treatment was seen to trigger the activation of specific T cells that can kill tumours. When the drug was combined with an immune activator bone metastasis was completely eliminated.

‘We have now identified how prostate cancer cells persist in bone, by specifically blocking immune proteins that reduce their visibility to the immune system. This opens the doors for new therapeutic approaches aimed at releasing the brakes on these immune pathways to target the cancer cells for immune destruction’ says Associate Professor Belinda Parker.

‘Future research will confirm whether use of agents that turn on IFN signalling in prostate cancer cells, including HDAC inhibitors, can be harnessed to offer new therapeutic opportunities in men with no current treatment options to combat bone metastasis through immune signalling restoration at the tumour cell level.’

The results from this study provide important information that can be built on to develop new treatments for men with advanced metastatic castrate resistant prostate cancer.

“This is a call to action," says PCFA CEO Professor Jeff Dunn. "Deaths from prostate cancer are avoidable, and we must not slow down the pace of work until Australia's fathers and sons are saved from this disease.

“The breakthrough demonstrates the tremendous value of Australian-based prostate cancer research towards a future free of prostate cancer.”  

How can you help?

This ground-breaking study was funded through a partnership with PCFA and the Movember foundation as a Movember Revolutionary Team Award. PCFA’s research program funds many projects like this that are crucial to understanding prostate cancer and how it can be better detected and treated. Our work is dependent on the generous support of the Australian public. Consider donating to prostate cancer research today and help us to support men with prostate cancer, their partners and families.

2 Comments
House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.